Trexquant Investment’s Array Biopharma Inc ARRY Stock Holding History

Trexquant Investment’s Portfolio ARRY Stock Details ARRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-52,639	Closed	-$1.28M	–	1303
2019 Q1	$1.28M	Sell	52,639 -12,970	-20%	-$270K	0.09%	324
2018 Q4	$935K	Sell	65,609 -56,678	-46%	-$860K	0.06%	440
2018 Q3	$1.86M	Buy	+122,287	New	+$1.87M	0.14%	221
2018 Q2	–	Sell	-17,697	Closed	-$289K	–	1397
2018 Q1	$289K	Sell	17,697 -96,116	-84%	-$1.54M	0.02%	823
2017 Q4	$1.46M	Buy	+113,813	New	+$1.29M	0.16%	189
2017 Q1	–	Sell	-41,332	Closed	-$363K	–	1439
2016 Q4	$363K	Buy	+41,332	New	+$304K	0.06%	565
2015 Q4	–	Sell	-204,612	Closed	-$933K	–	1390
2015 Q3	$933K	Buy	204,612 +124,119	+154%	+$736K	0.08%	448
2015 Q2	$580K	Sell	80,493 -5,719	-7%	-$42.2K	0.07%	548
2015 Q1	$635K	Buy	+86,212	New	+$614K	0.06%	594

Other funds holding ARRY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Trexquant Investment's ARRY Position: Q2 2019 in Review

Trexquant Investment sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 52,639 shares — an estimated $1.28M sold.

Trexquant Investment first reported a position in ARRY in Q1 2015 and held it in 9 quarters. The position peaked at $1.86M in Q3 2018. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

Trexquant Investment reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
Trexquant Investment sold 52,639 Array Biopharma Inc shares in Q2 2019, an estimated $1.28M.
Trexquant Investment first reported a position in Array Biopharma Inc in Q1 2015 and held it in 9 quarters.
Trexquant Investment's Array Biopharma Inc position peaked at $1.86M in Q3 2018.
318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Trexquant Investment's 13F filing for Q2 2019, filed 9 Aug 2019.